Citeline：2024年JPM医疗健康大会预览报告（中译版）（20页）.pdf

1、Pre-Event Report:Conference Preview#JPM24Preview ReportThe most influential healthcare summit is about to begin.Weve selected our picks of who to watch and what to look out for.Sponsored by#JPM24 Preview Report 2 January 2024 Copyright 2024 Pharma Intelligence UK Limited(Citeline),a Norstella compan

2、y(Unauthorized photocopying prohibited)Biotech Innovation Drives Industry Changes In Healthcare Foreword by Chris Smyth,President,ICON Biotech Numerous advancements have impacted clinical development over the past year,including new modalities,breakthrough technologies,digital transformation,and nov

3、el clinical trial designs.We continue to see immense growth potential in the biotech industry with never-before-seen CRISPR technology and robust cell and gene therapies progressing through late-stage clinical trials;however,we also see challenges with increased market competition and lack of fundin

4、g for more complex treatments.In order to keep pace with innovation,it is becoming imperative for life sciences companies to make the necessary strategic pivots that will get products to the finish line more efficiently.As the worlds largest clinical research organization(CRO),ICON provides support

5、and expertise to help companies mitigate the costs and risks associated with clinical development.We offer flexible partnership models that inform decision-making through extensive data resources and integrated clinical capabilities.From helping an emerging biotech meet its milestones,to assisting w

6、ith the global launch of a first-in-class drug,our healthcare intelligence is what differentiates us from other CROs.Regulation,manufacturing,and other parts of clinical development are growing more difficult to juggle as complexity rises,especially for smaller biotechs.With 8,000 experts working in